Actively Recruiting
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-15
150
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying high-grade serous ovarian carcinoma (HGSOC) to understand the role of ribosomal protein L8 (RPL8) gene alterations in this cancer. Preliminary findings suggest that RPL8 gene amplification occurs frequently in HGSOC and may influence cancer development. The study aims to explore whether RPL8 can serve as a biomarker for assessing risk and guiding treatment decisions by examining its genetic status and its link to clinical outcomes and treatment response. The research involves analyzing tumor tissue samples from ovarian cancer surgeries, including previously collected and newly gathered specimens. Laboratory tests will measure RPL8 and related gene expressions, gene copy numbers, and mutations through methods like RT-PCR, ddPCR, Western blotting, and immunohistochemistry. The study will correlate these molecular findings with patients' pathological data, follow-up information, and treatment responses. Participants diagnosed with high-grade serous ovarian carcinoma will have their tumor samples studied retrospectively and prospectively. Researchers will review medical history, clinical status, and outcomes using statistical tests to find relationships between RPL8 gene status and patient data. The primary outcome measure is the RPL8 status evaluated two years after enrollment. This observational study is led by IRCCS Azienda Ospedaliero-Universitaria di Bologna and involves ongoing collection and analysis of data to better understand this cancer type.
CONDITIONS
Brief Title
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with high-grade (3 or 4) serous ovarian carcinoma at onset or recurrence
- Provided signed informed consent to participate in the study
You will not qualify if you...
- Having ovarian tumors of histological types other than serous
- Having other primary tumor types
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies depending on tissue availability
Participants provide tumor tissue samples from ovarian cancer resections for analysis.
1 to 2 visits depending on tissue collection timing
Duration - Up to 2 years after enrollment
Analysis of RPL8, C-MYC, and related genes including gene amplification and expression levels using molecular techniques.
No specific visits; analysis performed on collected samples
Duration - Up to 2 years after enrollment
Participants' clinical outcomes and therapeutic responses are observed and correlated with genetic data over time.
Periodic assessments as part of routine care
Trial Site Locations
Total: 1 location
1
IRCCS Azianda Ospedaliero-Universitaria di Bologna
Bologna, BO, Italy, 40138
Actively Recruiting
Research Team
L
Lorenzo Montanaro, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here